Literature DB >> 23291901

Regulation of retinal endothelial cell apoptosis through activation of the IGFBP-3 receptor.

Qiuhua Zhang1, Carl Soderland, Jena J Steinle.   

Abstract

The goal of this study was to investigate whether insulin-like growth factor binding protein-3 receptor (IGFBP-3 receptor) is required for IGFBP-3 to inhibit retinal endothelial cell (REC) apoptosis. REC were grown in normal glucose (5 mM) or high glucose medium (25 mM) for 3 days. Once cells reached confluence, they were transfected with an endothelial- specific IGFBP-3 plasmid DNA (non-IGF binding; IGFBP-3 NB) at 1 μg/ml for 24 h. Cell proteins were extracted and analyzed for IGFBP-3 receptor expression by Western blotting or use in coimmunoprecipitation or co-localization experiments for detection of IGFBP-3 and IGFBP-3 receptor binding. REC were also transfected with or without IGFBP-3 receptor siRNA before IGFBP-3NB plasmid DNA transfection. Cell lysates were processed for a cell death ELISA, a cleaved caspase 3 ELISA, and Western blotting to measure key pro- and anti-apoptotic markers: Bcl-xL, Bax, Cytochrome C and Akt. The IGFBP-3 receptor is present on REC. Overexpression of IGFBP-3 in REC significantly increased protein levels of IGFBP-3 receptor (p < 0.05). Significant increases in cell death were found in cells transfected with IGFBP-3 receptor siRNA versus not treated samples (p < 0.05). Data suggest that IGFBP-3 inhibits retinal endothelial cell death through activation of an IGFBP-3 receptor in a hyperglycemic environment. This is the first demonstration of the involvement of IGFBP-3 receptor in inhibition of REC cell death. Future studies will investigate the mechanism by which IGFBP-3 receptor may inhibit retinal endothelial cell death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23291901      PMCID: PMC4026254          DOI: 10.1007/s10495-012-0793-3

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  35 in total

1.  Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer.

Authors:  Angela R Ingermann; Yong-Feng Yang; Jinfeng Han; Aki Mikami; Amanda E Garza; Lathika Mohanraj; Lingbo Fan; Michael Idowu; Joy L Ware; Ho-Seong Kim; Dae-Yeol Lee; Youngman Oh
Journal:  J Biol Chem       Date:  2010-03-30       Impact factor: 5.157

2.  Vitreous IGFBP-3 effects on Müller cell proliferation and tractional force generation.

Authors:  Jeffery L King; Clyde Guidry
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-05       Impact factor: 4.799

Review 3.  Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics.

Authors:  Jean-Claude Martinou; Richard J Youle
Journal:  Dev Cell       Date:  2011-07-19       Impact factor: 12.270

4.  Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells.

Authors:  Lujia Gribben; Robert C Baxter; Deborah J Marsh
Journal:  Cancer Lett       Date:  2011-11-13       Impact factor: 8.679

5.  Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.

Authors:  Jai-Hyun Kim; Dong Soon Choi; Ok-Hee Lee; Seung-Hyun Oh; Scott M Lippman; Ho-Young Lee
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

6.  Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels.

Authors:  Qiuhua Zhang; Kimberly Guy; Jayaprakash Pagadala; Youde Jiang; Robert J Walker; Luhong Liu; Carl Soderland; Timothy S Kern; Robert Ferry; Hui He; C Ryan Yates; Duane D Miller; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

7.  Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-κB signaling through IGFBP-3R-mediated activation of caspases.

Authors:  Yong-Chul Lee; Sherryline Jogie-Brahim; Dae-Yeol Lee; Jinfeng Han; Aki Harada; Liam J Murphy; Youngman Oh
Journal:  J Biol Chem       Date:  2011-03-07       Impact factor: 5.157

8.  Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury.

Authors:  Jennifer L Kielczewski; Ping Hu; Lynn C Shaw; Sergio Li Calzi; Robert N Mames; Tom A Gardiner; Evan McFarland; Tailoi Chan-Ling; Maria B Grant
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

Review 9.  Unraveling insulin-like growth factor binding protein-3 actions in human disease.

Authors:  Sherryline Jogie-Brahim; David Feldman; Youngman Oh
Journal:  Endocr Rev       Date:  2009-05-28       Impact factor: 19.871

10.  Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.

Authors:  Fiona M Regan; Rachel M Williams; Anna McDonald; A Margot Umpleby; Carlo L Acerini; Stephen O'Rahilly; Roman Hovorka; Robert K Semple; David B Dunger
Journal:  J Clin Endocrinol Metab       Date:  2010-03-16       Impact factor: 5.958

View more
  11 in total

1.  Pioglitazone restores IGFBP-3 levels through DNA PK in retinal endothelial cells cultured in hyperglycemic conditions.

Authors:  Shalini Thakran; Qiuhua Zhang; Vanessa Morales-Tirado; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-18       Impact factor: 4.799

2.  Insulin-like growth factor-1 binding protein 3 (IGFBP-3) promotes recovery from trauma-induced expression of inflammatory and apoptotic factors in retina.

Authors:  Youde Jiang; Jayaprakash Pagadala; Duane D Miller; Jena J Steinle
Journal:  Cytokine       Date:  2014-07-28       Impact factor: 3.861

3.  IGFBP-3 inhibits TNF-α production and TNFR-2 signaling to protect against retinal endothelial cell apoptosis.

Authors:  Qiuhua Zhang; Jena J Steinle
Journal:  Microvasc Res       Date:  2014-07-30       Impact factor: 3.514

4.  IGFBP-3 and TNF-α regulate retinal endothelial cell apoptosis.

Authors:  Qiuhua Zhang; Youde Jiang; Matthew J Miller; Bonnie Peng; Li Liu; Carl Soderland; Jie Tang; Timothy S Kern; John Pintar; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-09       Impact factor: 4.799

5.  VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1.

Authors:  Haoshen Shi; Thomas W Carion; Youde Jiang; Jena J Steinle; Elizabeth A Berger
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-03-26       Impact factor: 3.072

6.  DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose.

Authors:  Qiuhua Zhang; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-30       Impact factor: 4.799

7.  IGF-Binding Proteins in Type-1 Diabetes Are More Severely Altered in the Presence of Complications.

Authors:  Ashok Sharma; Sharad Purohit; Shruti Sharma; Shan Bai; Wenbo Zhi; Sithara Raju Ponny; Diane Hopkins; Leigh Steed; Bruce Bode; Stephen W Anderson; Jin-Xiong She
Journal:  Front Endocrinol (Lausanne)       Date:  2016-01-29       Impact factor: 5.555

8.  The quinic acid derivative KZ-41 prevents glucose-induced caspase-3 activation in retinal endothelial cells through an IGF-1 receptor dependent mechanism.

Authors:  Hui He; Rebecca L Weir; Jordan J Toutounchian; Jayaprakash Pagadala; Jena J Steinle; Jerome Baudry; Duane D Miller; Charles R Yates
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

9.  Intravitreal injection of IGFBP-3 restores normal insulin signaling in diabetic rat retina.

Authors:  Youde Jiang; Qiuhua Zhang; Jena J Steinle
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

10.  Gene expression of IGF1, IGF1R, and IGFBP3 in epiretinal membranes of patients with proliferative diabetic retinopathy: preliminary study.

Authors:  Dorota Romaniuk; Malgorzata W Kimsa; Barbara Strzalka-Mrozik; Magdalena C Kimsa; Adam Kabiesz; Wanda Romaniuk; Urszula Mazurek
Journal:  Mediators Inflamm       Date:  2013-11-28       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.